Kyverna Therapeutics (KYTX) Capital Expenditures (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Capital Expenditures data on file, last reported at $5000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 99.03% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $618000.0 (down 74.04% YoY) and the FY2025 annual result came in at $1.1 million, down 42.3% from the prior year.
• Capital Expenditures eased to $5000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q4 2023 to a low of -$499000.0 in Q3 2025.
• A 4-year average of $379769.2 and a median of $89000.0 in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 478.65% in 2025, down 150.15% in 2025.
• Tracing KYTX's Capital Expenditures over 4 years: stood at $1.6 million in 2023, then plunged by 38.54% to $960000.0 in 2024, then gained by 16.88% to $1.1 million in 2025, then tumbled by 99.55% to $5000.0 in 2026.
• The last three Capital Expenditures figures came in at $5000.0 (Q1 2026), $1.1 million (Q4 2025), and -$499000.0 (Q3 2025), per Business Quant data.